Mycophenolic acid therapeutic drug monitoring using area under the curve in pediatric heart transplant recipients
© 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd..
INTRODUCTION: Pharmacokinetics of mycophenolic acid (MPA) display substantial interpatient variability, with up to 10-fold difference of exposure in individual patients under a fixed-dose regimen. MPA trough level (C0) monitoring is common in clinical practice but has not proven sufficiently informative in predicting MPA exposure or patient outcomes, especially in children. No limited sampling strategies (LSSs) have been generated from pediatric heart transplant (HTx) recipients to estimate MPA AUC.
METHODS: Single-center, observational analysis of 135 de novo pediatric HTx recipients ≤21 years old who underwent MPA AUC between 2011 and 2021.
RESULTS: Median age was 4 years (IQR .6-12.1). Median time from transplant to MPA AUC sampling was 15 days (IQR 11-19). MMF doses (mg or mg/day) had low, negative Pearson correlation coefficients (r) while doses adjusted for weight or body surface area had low correlation with Trapezoidal MPA AUC0-24 h (r = .3 and .383, respectively). MPA C0 had weak association (r = .451) with Trapezoidal MPA AUC0-24 h . LSS with two pharmacokinetic sampling time points at 90 (C3 ) and 360 (C5 ) min after MMF administration (estimated AUC0-24 h = 32.82 + 4.12 × C3 + 11.53 × C5 ) showed strong correlation with Trapezoidal MPA AUC0-24 h (r = .87).
CONCLUSION: MMF at fixed or weight-adjusted doses, as well as MPA trough levels, correlate poorly with MPA AUC0-24 h . We developed novel LSSs to estimate Trapezoidal MPA AUC from a large cohort of pediatric HTx recipients. Validation of our LSSs should be completed in a separate cohort of pediatric HTx recipients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
Clinical transplantation - 37(2023), 11 vom: 01. Nov., Seite e15087 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Newland, David M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Area under the curve |
|---|
| Anmerkungen: |
Date Completed 13.11.2023 Date Revised 29.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/ctr.15087 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360263690 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360263690 | ||
| 003 | DE-627 | ||
| 005 | 20231226082637.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/ctr.15087 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1200.xml |
| 035 | |a (DE-627)NLM360263690 | ||
| 035 | |a (NLM)37526562 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Newland, David M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mycophenolic acid therapeutic drug monitoring using area under the curve in pediatric heart transplant recipients |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.11.2023 | ||
| 500 | |a Date Revised 29.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. | ||
| 520 | |a INTRODUCTION: Pharmacokinetics of mycophenolic acid (MPA) display substantial interpatient variability, with up to 10-fold difference of exposure in individual patients under a fixed-dose regimen. MPA trough level (C0) monitoring is common in clinical practice but has not proven sufficiently informative in predicting MPA exposure or patient outcomes, especially in children. No limited sampling strategies (LSSs) have been generated from pediatric heart transplant (HTx) recipients to estimate MPA AUC | ||
| 520 | |a METHODS: Single-center, observational analysis of 135 de novo pediatric HTx recipients ≤21 years old who underwent MPA AUC between 2011 and 2021 | ||
| 520 | |a RESULTS: Median age was 4 years (IQR .6-12.1). Median time from transplant to MPA AUC sampling was 15 days (IQR 11-19). MMF doses (mg or mg/day) had low, negative Pearson correlation coefficients (r) while doses adjusted for weight or body surface area had low correlation with Trapezoidal MPA AUC0-24 h (r = .3 and .383, respectively). MPA C0 had weak association (r = .451) with Trapezoidal MPA AUC0-24 h . LSS with two pharmacokinetic sampling time points at 90 (C3 ) and 360 (C5 ) min after MMF administration (estimated AUC0-24 h = 32.82 + 4.12 × C3 + 11.53 × C5 ) showed strong correlation with Trapezoidal MPA AUC0-24 h (r = .87) | ||
| 520 | |a CONCLUSION: MMF at fixed or weight-adjusted doses, as well as MPA trough levels, correlate poorly with MPA AUC0-24 h . We developed novel LSSs to estimate Trapezoidal MPA AUC from a large cohort of pediatric HTx recipients. Validation of our LSSs should be completed in a separate cohort of pediatric HTx recipients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a area under the curve | |
| 650 | 4 | |a limited sampling strategy | |
| 650 | 4 | |a mycophenolic acid | |
| 650 | 4 | |a pediatric heart transplant | |
| 650 | 4 | |a therapeutic drug monitoring | |
| 650 | 7 | |a Mycophenolic Acid |2 NLM | |
| 650 | 7 | |a HU9DX48N0T |2 NLM | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 700 | 1 | |a Pak, Jennifer L |e verfasserin |4 aut | |
| 700 | 1 | |a Ali, Reda |e verfasserin |4 aut | |
| 700 | 1 | |a Herzog, Thiebaut |e verfasserin |4 aut | |
| 700 | 1 | |a Nemeth, Thomas L |e verfasserin |4 aut | |
| 700 | 1 | |a Tressel, William |e verfasserin |4 aut | |
| 700 | 1 | |a Kronmal, Richard A |e verfasserin |4 aut | |
| 700 | 1 | |a Knorr, Lisa R |e verfasserin |4 aut | |
| 700 | 1 | |a Albers, Erin L |e verfasserin |4 aut | |
| 700 | 1 | |a Friedland-Little, Joshua M |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmed, Humera |e verfasserin |4 aut | |
| 700 | 1 | |a Kemna, Mariska S |e verfasserin |4 aut | |
| 700 | 1 | |a Hong, Borah J |e verfasserin |4 aut | |
| 700 | 1 | |a Spencer, Kathryn |e verfasserin |4 aut | |
| 700 | 1 | |a Law, Yuk M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical transplantation |d 1987 |g 37(2023), 11 vom: 01. Nov., Seite e15087 |w (DE-627)NLM07493306X |x 1399-0012 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2023 |g number:11 |g day:01 |g month:11 |g pages:e15087 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/ctr.15087 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2023 |e 11 |b 01 |c 11 |h e15087 | ||